Policy & Regulation
Trevi Therapeutics Names Christopher J. Seiter as CFO
18 May 2018 - - New Haven Connecticut-based late-stage biopharmaceutical company Trevi Therapeutics, Inc. has named Christopher J. Seiter as chief financial officer, the company said.
Seiter will be responsible for the finance, treasury, and accounting functions of the company.
Seiter has over two decades of experience in the healthcare industry. He most recently served as CFO of Millendo Therapeutics.
He previously spent 23 years in investment banking, and also served in the US Navy as a nuclear submarine officer for five years.
Trevi is focused on developing the synthetic opiod Nalbuphine ER for chronic pruritic conditions. The company is pursuing several pruritic conditions, including pruritis nodularis, for which there is no approved treatment in the US or EU.
Nalbuphine ER is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch.
Login
Username:

Password: